Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 18, 2005, Pages 5346-5361

  Gudmundsson, Kristjan S ^a   Johns, Brian A ^a   Wang, Zhicheng ^a   Turner, Elizabeth M ^a   Allen, Scott H ^a   Freeman, George A ^a   Boyd Jr , F Leslie ^a   Sexton, Connie J ^a   Selleseth, Dean W ^a   Moniri, Kelly R ^a   Creech, Katrina L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Anti viral compounds; Herpesviruses; Pyrazolopyridines

Indexed keywords

2 (2 BROMOPHENYL) N CYCLOPENTYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1, 5 A]PYRIDIN 7 AMINE; 2 (3 AMINOPHENYL) N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 (3 BROMOPHENYL) N CYCLOPENTYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1, 5 A]PYRIDIN 7 AMINE; 2 (3 CHLOROPHENYL) N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 (4 BROMOPHENYL) N BUTYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 (4 BUTOXYPHENYL) N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 (4 CHLOROPHENYL) N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 [4 (ALLYLOXY)PHENYL] N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; 2 [4 (CYCLOBUTYLMETHOXY)PHENYL] N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRINDIN 7 AMINE; 3 [7 (CYCLOPENTYLAMINO) 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 2 YL]BENZAMIDE; 3 [7 (CYCLOPENTYLAMINO) 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 2 YL]PHENOL; ACICLOVIR; ETHYL[4 [7 (CYCLOPENTYLAMINO) 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 2 YL]PHENOXY]ACETATE; N [3 [7 (CYCLOPENTYLAMINO) 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] PYRAZOLO[1,5 A]PYRIDIN 2 YL]PHENYL]ACETAMIDE; N [3 [7 (CYCLOPENTYLAMINO) 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] PYRAZOLO[1,5 A]PYRIDIN 2 YL]PHENYL]METHANESULFONAMIDE; N [4 [2 (4 AMINOPHENYL) 7 (BUTYLAMINO) PYRAZOLO (1,5 ALPHA) PYRIDIN 3 YL] 2 PYRIMIDINYL] N BUTYLAMINE; N BUTYL 3 [2 (BUTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N BUTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL) PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (3 METHOXYPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (3 METHYLPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 FLUOROPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 ISOBUTOXYPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 METHYLPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 (4 PHENOXYPHENYL)PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 [3 (CYCLOPROPHYLMETHOXY) PHENYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 [4 (CYCLOPROPHYL METHOXY) PHENYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL] 2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 7 AMINE; N CYCLOPENTYL 3 [2 (CYCLOPENTYLAMINO) 4 PYRIMIDINYL]PYRAZOLO[1,5 A]PYRIDIN 7 AMINE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; NONHUMAN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOL; PYRAZOLES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2;

EID: 23644462264     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.05.043     Document Type: Article

References (47)

1. B. Roizman, and P.E. Pellett D.M. Knipe P.M. Howley Fields Virology Vol. 2 2001 Lippincott Williams and Wilkins Philadelphia, PA 2381
2. L. Corey, and P. Spear New Engl. J. Med. 314 1986 686
3. L. Corey, and H.H. Handsfield J. Am. Med. Assoc. 283 2000 791
4. G. Kleymann Expert Opin. Investig. Drugs 12 2003 165 183
5. Y. Becker Virus Genes 24 2002 187 196
6. M.D. Moomaw, P. Cornea, R.C. Rathbun, and K.A. Wendel Expert Rev. Anti-infect. Ther. 1 2003 283
7. S.M. Firestine Expert Opin. Ther. Patents 14 2004 1139
8. B. Roizman, and R.J. Whitley Herpes 8 2001 23
9. H.E. Kaufman Prog. Retin. Eye Res. 19 2000 69
10. G.B. Elion, P.A. Furman, J.A. Fyfe, P. De Miranda, L. Beauchamp, and H.J. Schaeffer Proc. Natl. Acad. Sci. USA 74 1977 5716
11. G.B. Elion J. Med. Virol. Suppl. 1 1993 2
12. K.R. Beutner Antiviral Res. 28 1995 281
13. C.M. Perry, and D. Faulds Drugs 52 1996 754
14. R.L. Jarvest, D. Sutton, and R.A. Vere Hodge Pharm. Biotechnol. 11 1998 313
15. L. Naesens, and E. De Clercq Herpes 8 2001 12
16. E.C. Villerreal Prog. Drug Res. 56 2001 77
17. R. Snoeck, and E. De Clercq Curr. Opin. Infect. Dis. 15 2002 49
18. L. Stanberry, A. Cunningham, and G. Mertz Antiviral Res. 42 1999 1
19. L.A. Morrison Drugs 62 2002 1119
20. S.K. Eo, C. Pack, U. Kumaraguru, and B.T. Rouse Expert Opin. Biol. Ther. 1 2001 213
21. J.A. Carr, J. Rogerson, M.J. Mulqueen, N.A. Roberts, and R.F. Booth J. Virol. 71 1997 7799
22. S. Noisakaran, and D.J. Carr Immunol. Res. 24 2001 1
23. S.M. Garland Curr. Opin. Infect. Dis. 16 2003 85
24. J. Taff Curr. Opin. Investig. Drugs 4 2003 214
25. S.L. Spruance, S.K. Tyring, M.H. Smith, and T.C. Meng J. Infect. Dis. 184 2001 196
26. N.L. Oien, R.J. Brideau, and T.A. Hopkins Antimicrob. Agents Chemother. 46 2002 724
27. R.J. Brideau, M.L. Knechtel, and A. Huang Antiviral Res 54 2002 19
28. M.W. Wathen Rev. Med. Virol. 12 2002 167
29. M. Jurk, R. Heil, and J. Vollmer Nat. Immunol. 3 2002 499
30. M.A. Stanley Clin. Exp. Dermatol. 27 2002 571
31. J.J. Crute, C.A. Grygon, K.D. Hargrave, B. Simoneau, A.-M. Faucher, G. Bolger, P. Kibler, M. Liuzzi, and M.G. Cordingley Nat. Med. 8 2002 386
32. G. Kleymann, R. Fischer, U.A.K. Betz, M. Hendrix, W. Bender, U. Schneider, G. Handke, and P. Eckenberg Nat. Med. 8 2002 392
33. B.A. Johns, K.S. Gudmundsson, E.M. Turner, S.A. Allen, D.K. Jung, C.J. Sexton, F.L. Boyd, and M.R. Peel Tetrahedron 59 2003 9001
34. Boyd, F. L.; Chamberlain, S. D.; Cheung, M.; Gudmundsson, K. S.; Harris, P. A.; Johns, B. A.; Jung, D. K.; Peel, M. R.; Stanford, J. B.; Sexton, C. J. WO 0248148, 2002.
35. B.A. Johns, K.S. Gudmundsson, E.M. Turner, S.H. Allen, V.A. Samano, J.A. Ray, G.A. Freeman, F.L. Boyd Jr., C.J. Sexton, D.W. Selleseth, K.L. Creech, and K.R. Moniri Bioorg. Med. Chem. 13 2005 2397
36. J.P. Wolfe, S. Wagaw, and S.L. Buchwald J. Am. Chem. Soc. 118 1996 7215
37. M.C. Harris, O. Geis, and S.L. Buchwald J. Org. Chem. 64 1999 6019
38. J.P. Wolfe, and S.L. Buchwald J. Org. Chem. 65 2000 1144
39. D.A. Evans, J.L. Katz, and T.R. West Tetrathedron Lett. 39 1998 2937
40. P.Y.S. Lam, C.G. Clark, S. Saubern, J. Adams, M.P. Winters, D.M.T. Chan, and A. Combs Tetrahedron Lett. 39 1998 2491
41. A. Suzuki Pure Appl. Chem. 57 1985 1749
42. M. Murata, S. Watanabe, and Y. Masuda J. Org. Chem. 60 1997 6458
43. P.E. Maligres, M.S. Waters, F. Fleitz, and D. Askin Tetrahedron Lett. 40 1999 8193
44. F. Jin, and P.N. Confalone Tetrahydron Lett. 41 2000 3271
45. Reaction conditions similar to those described in: K.S. Gudmundsson, Z. Wang, S.M. Daluge, and P.F. Feldman Nucleosides Nucleotides Nucleic Acids 20 2001 1823
46. Based on studies where compound was added to the cell cultures at different timepoints after infection. More detailed description of virology studies will be the subject of future publications.
47. S. Weiss, and H. Krommer Chem.-Ztg. 98 1974 617